TeraImmune, Inc is a pre-clinical stage immune cell therapeutics company structured around development of the regulatory T cell (Treg) therapy in hemophilia A (HA) with FVIII anti-drug antibody (ADA); Multiple Sclerosis, and graft-versus-host disease from stem cell transplantation. The firm's work is anchored. in part .in a patent portfolio licensed from the National Institutes of Health and the Henry Jackson Foundation. Regulatory T cells (Tregs) - previously known as suppressor T cells, - are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Tregs are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.
